ICU (SeaStar Medical Holding) Cash, Cash Equivalents, Marketable Securities : $5.30 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is SeaStar Medical Holding Cash, Cash Equivalents, Marketable Securities?

SeaStar Medical Holding's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 ($2.08 Mil) to Dec. 2024 ($1.82 Mil) but then increased from Dec. 2024 ($1.82 Mil) to Mar. 2025 ($5.30 Mil).

SeaStar Medical Holding's annual cash, cash equivalents, marketable securities increased from Dec. 2022 ($0.05 Mil) to Dec. 2023 ($0.18 Mil) and increased from Dec. 2023 ($0.18 Mil) to Dec. 2024 ($1.82 Mil).

SeaStar Medical Holding Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for SeaStar Medical Holding's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SeaStar Medical Holding Cash, Cash Equivalents, Marketable Securities Chart

SeaStar Medical Holding Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

2.81

0.51

0.05

0.18

1.82

SeaStar Medical Holding Quarterly Data
	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial												5.02	1.18	2.08	1.82	5.30

SeaStar Medical Holding Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

SeaStar Medical Holding (NAS:ICU) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

SeaStar Medical Holding Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of SeaStar Medical Holding's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

SeaStar Medical Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SeaStar Medical Holding Corp (NAS:ICU) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216

Website

https://www.seastarmedical.com

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Executives

Kevin Chung	officer: Chief Medical Officer	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Heel Kenneth Van	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Richard D. Russell	director	3201 W BAY VISTA AVE, TAMPA FL 33611
Bruce M. Rodgers	director	302 KNIGHTS RUN AVE., STE. 1000, TAMPA FL 33602
Andres Lobo	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Caryl Baron	officer: See Remarks	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Eric Schlorff	director, officer: Chief Executive Officer	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Rick Barnett	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Allan Collins	director	C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216
Dow Employees' Pension Plan Trust	10 percent owner	2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Union Carbide Employees' Pension Plan Trust	10 percent owner	2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674
Martin A Traber	director	100 N TAMPA STREET, SUITE 2700, TAMPA FL 33602
Lm Funding America, Inc.	10 percent owner	1200 WEST PLATT STREET, SUITE 100, TAMPA FL 33606
Craig E Burson	director	400 N. PARK AVENUE, UNIT 10B, BRECKENRIDGE CO 80424
Bruce H Bennett	director	3929 ARLINGTON DRIVE, PALM HARBOR FL 34685